Outlook Therapeutics Inc OTLK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
-
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
-
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
-
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
-
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
-
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
-
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
-
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
Trading Information
- Previous Close Price
- $0.56
- Day Range
- $0.51–0.56
- 52-Week Range
- $0.16–2.54
- Bid/Ask
- $0.53 / $0.53
- Shares Outstanding
- 243.45M
- Market Cap
- $126.42M
- Volume/Avg
- 3M / 12M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
Valuation
|
Metric
|
OTLK
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OTLK
|
|---|---|
Quick Ratio | 0.45 |
Current Ratio | 0.81 |
Interest Coverage | −358.38 |
Quick Ratio
OTLK
Profitability
|
Metric
|
OTLK
|
|---|---|
Return on Assets (Normalized) | −233.55% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −276,145.73% |
Return on Assets
OTLK
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Kq<@vN | LOCK|!W#!K | $136B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|ssNb@N | LOCK|>KD@# | $84B | |||
| Moderna Inc
MRNA
| LOCK|!RXVcP | LOCK|^dN | $81B | |||
| argenx SE ADR
ARGX
| LOCK|CY&J$? | LOCK|!b | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?DdgRRV | LOCK|^t | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|FfB?K^ | LOCK|^>^P | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|cl^Mh&x | LOCK|BWx$ | $28B | |||
| Incyte Corp
INCY
| LOCK|$<#%w## | LOCK|TZ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|F?%Bw& | LOCK|@G& | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|PtNyqp | LOCK|ncT | $14B |
United States